Effects of short-term atorvastatin treatment on global fibrinolytic capacity, and sL-selectin and sFas levels in hyperlipidemic patients with coronary artery disease

International Journal of Cardiology

Volumn 84, Issue 2-3, 2002, Pages 227-231

  Atalar, Enver ^a   Ozmen, Ferhan ^a   Haznedaroǧlu, Ibrahim ^a   Açil, Tayfun ^a   Ozer, Necla ^a   Ovünç, Kenan ^a   Aksöyek, Serdar ^a   Kes, Sirri ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Apoptosis; Fibrinolytic system; Hmg CoA reductase inhibitors; Leukocyte activation; Serum lipoproteins; Statins

Indexed keywords

ATORVASTATIN; CHOLESTEROL; FAS ANTIGEN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; SELECTIN; TRIACYLGLYCEROL;

ADULT; APOPTOSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; FEMALE; FIBRINOLYSIS; HUMAN; HYPERLIPIDEMIA; LEUKOCYTE ACTIVATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SHORT COURSE THERAPY; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR SMOOTH MUSCLE;

ADULT; ANTICHOLESTEREMIC AGENTS; APOPTOSIS; CHOLESTEROL; CORONARY ARTERIOSCLEROSIS; FATTY ACIDS; FEMALE; FIBRINOLYSIS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; L-SELECTIN; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PYRROLES; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 0036077691     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(02)00148-1     Document Type: Article

References (28)

1. Effects of statins on vascular wall: Vasomotor function, inflammation, and plaque stability
2. The evolving role of statins in the management of atherosclerosis
3. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study
4. Prevention of coronary heart disease with pravastatin in men with hypercholestrolemia
5. Influence of pravastain and plasma lipids on clinical events in the West of Scotland Prevention Study (WOSCOPS)
6. Statins do more than just lower cholesterol
7. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). The MARS Research Group
8. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis
9. Monocyte expression of proinflammatory cytokines in patients with hypercholestrolemia
10. Hyperlipidemia and coronary disease: Correction of the increased thrombogenic potential with cholesterol reduction
11. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
12. Evaluation of the fibrinolytic potential on plasma: Physiological and pathological variations, and associations with cardiovascular disease risk factors
13. Pravastatin therapy in hyperlipidemia: Effects on thrombus formation and the systemic hemostatic profile
14. Antiatherothrombotic properties of statins
15. Effects of atorvastatin on plasma fibrinogen
16. Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients
17. Effect of atorvastatin versus simvastatin on lipid profile and plasma fibrinogen in patients with hypercholestrolemia. A pilot, randomized, double blind, dose-titrating study
18. Fibrinogen response with simvastatin versus atorvastatin in familial hypercholestrolemia
19. Control of plasma fibrinogen levels
20. Beta fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction: The ECTIM Study
21. Seasonal variations of rheological and hemostatic parameters and acute-phase reactants in young, healthy subjects
22. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys
23. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages
24. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholestrolemic rats
25. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule
26. Soluble cytokine receptors
27. The role of Fas/APO 1 and apoptosis in the development of human atherosclerotic lesions
28. Involvement of the Fas death-signalling pathway in cytokine-induced apoptosis of vascular smooth muscle cells during atherogenesis